Referring to cancer as a “battle” minimizes the many real issues faced by cancer patients who must live with nausea, pain, ...

Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...

New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer ...

Nearly half of the most popular protein powders on the market tested positive for higher-than-safe levels of heavy metals, ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...